DARE: Diabetes in cArdiac REhabilitation

NCT ID: NCT00354237

Last Updated: 2014-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-07-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the DARE study is to see whether strict glycemic control during cardiac rehabilitation may ameliorate the improvement of exercise capacities (VO2 peak, peak workload, ventilatory threshold)in patients with type 2 diabetes with coronary artery disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In a recent study, we showed that the benefit of cardiac rehabilitation on the improvement of exercise capacities (VO2 peak, peak workload, ventilatory threshold), after an acute coronary event, was significantly reduced in patients with type 2 diabetes. Moreover ,we showed, in multivariate analysis, that the worse improvement of the capacities to the effort after cardiac rehabilitation, was mainly related to hyperglycemia.

Because the improvement of exercise capacities after cardiac rehabilitation (in particular VO2 peak) has been shown to be an essential factor to reduce short- term and long-term morbidity and mortality, we may think that such benefit on reduction of morbidity and mortality may be significantly less in patients with diabetes.

Thus, we propose to carry out a multicentric intervention study, entitled DARE which goal is to see whether a strict glycemic control, during cardiac rehabilitation following an acute Myocardial Infarction (MI), is likely to improve, the results of cardiac rehabilitation on exercise capacities in patients with type 2 diabetes.

After arrival in cardiac rehabilitation, patients with diabetes, will be randomized into 2 groups: an "intensive treatment" group, in which the patients will treated by insulin under a basal-bolus regimen with strict glycemic control and a "conventional treatment" group, in which the previous anti-diabetic treatment will be continued.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

B

No intensive treatment

Group Type OTHER

Conventional antidiabetic treatment

Intervention Type OTHER

No intensive treatment

A

Intensive insulin treatment

Group Type EXPERIMENTAL

Intensive insulin treatment

Intervention Type OTHER

Intensive insulin treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Conventional antidiabetic treatment

No intensive treatment

Intervention Type OTHER

Intensive insulin treatment

Intensive insulin treatment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetes mellitus
* recent Miocardial Infarction
* HbA1c above 7%
* enrolled in a cardiac rehabilitation program

Exclusion Criteria

* Type 1 diabetes
* Coronary Bypass Surgery
* Renal Failure (creatinine clearance below 30 ml/min)
* severe Respiratory Failure
Minimum Eligible Age

25 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire Dijon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof. Bruno Vergès

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bruno L Vergès, Prof

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier Universitaire Dijon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre hospitalier du pays d'Aix

Aix-en-Provence, , France

Site Status

Clinique Rhône Durance

Avignon, , France

Site Status

Hôpital J Minjoz

Besançon, , France

Site Status

CMC Bligny

Briis-sous-Forges, , France

Site Status

centre de réadaptation cardiaque "Château le moine"

Cenon, , France

Site Status

CHU du Bocage

Dijon, , France

Site Status

Centre IRIS

Marcy-l'Étoile, , France

Site Status

Centre Hospitalier de MONTBARD

Montbard, , France

Site Status

Hopital BROUSSAIS, APHP

Paris, , France

Site Status

Hôpital du haut Lévêque

Pessac, , France

Site Status

Rééducation cardiovasculaire CRF Kerpape

Ploemeur, , France

Site Status

Hôpital jeanne d'arc

Toul, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Verges B, Patois-Verges B, Iliou MC, Simoneau-Robin I, Bertrand JH, Feige JM, Douard H, Catargi B, Fischbach M; DARE Study group. Influence of glycemic control on gain in VO2 peak, in patients with type 2 diabetes enrolled in cardiac rehabilitation after an acute coronary syndrome. The prospective DARE study. BMC Cardiovasc Disord. 2015 Jul 8;15:64. doi: 10.1186/s12872-015-0055-8.

Reference Type DERIVED
PMID: 26152221 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DGS2005/0130

Identifier Type: -

Identifier Source: org_study_id